SCHEMBL6693465

SCHEMBL6693465

COc1ccc(-c2nc(-c3ccccc3)cs2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.75
KDM4E B2RXH2 4/20 0.75
ATM Q13315 2/20 0.75
POLB P06746 2/20 0.75
RAB9A P51151 7/20 0.72
SMN1; SMN2 Q16637 6/20 0.72
NPC1 O15118 5/20 0.72
ALDH1A1 P00352 3/20 0.72
CYP19A1 P11511 2/20 0.72
SREBF2 Q12772 1/20 0.69
KMT2A Q03164 4/20 0.66
MEN1 O00255 3/20 0.66
NFKB1 P19838 3/20 0.66
NFKB2 Q00653 3/20 0.66
RELA Q04206 3/20 0.66
CDC25A P30304 1/20 0.65
CDC25B P30305 1/20 0.65
AR P10275 1/20 0.63
CYP1A1 P04798 1/20 0.62
CYP1B1 Q16678 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13458065 0.98 MAPT (0.73) MAPTKDM4EATMPOLBRAB9A
SCHEMBL1180215 0.93 MAPT (0.84) MAPTKDM4EATMPOLBRAB9A
SCHEMBL19196285 0.90 CYP19A1 (0.64) MAPTKDM4EATMPOLBRAB9A
SCHEMBL4279335 0.88 MAPT (0.74) MAPTKDM4EATMPOLBRAB9A
SCHEMBL28534175 0.87 KDM4E (0.75) MAPTKDM4EATMPOLBRAB9A
SCHEMBL4279334 0.87 KDM4E (0.75) MAPTKDM4EATMPOLBRAB9A
SCHEMBL1180576 0.86 CYP19A1 (0.71) MAPTKDM4EATMPOLBRAB9A
Pyrrole SCHEMBL3654122 0.86 KDM4E (0.69) MAPTKDM4EATMPOLBRAB9A
SCHEMBL1181045 0.86 CYP19A1 (0.67) MAPTKDM4EATMPOLBRAB9A
SCHEMBL11212983 0.86 SREBF2 (0.82) MAPTKDM4EPOLBRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10011573-B2 Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2018-07-03 US disclosed
US-20170183319-A1 HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-06-29 US disclosed
WO-2015120543-A1 HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAIN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-08-20 WO disclosed
US-20040248950-A1 Apo ai expression accelerating agent SHIONOGI & CO., LTD. (JP) 2004-12-09 US disclosed
EP-1419770-A1 APO AI EXPRESSION ACCELERATING AGENT SHIONOGI & CO., LTD. (JP) 2004-05-19 EP disclosed
US-4197306-A CONTROL OF INSECTS AND ACARIDS UNIROYAL, INC. (US) 1980-04-08 US disclosed
US-4153703-A Method of controlling insects and acarids with certain aryl-substituted thiazoles UNIROYAL, INC. (US) 1979-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011573-B2 Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use AR, SHBG, BRCA1 MAPT 2875/4885KDM4E 1638/4885ATM 695/4885
US-20040248950-A1 Apo ai expression accelerating agent APOB, APOL1, NR1H2 MAPT 4864/4885KDM4E 4259/4885ATM 3513/4885
US-20170183319-A1 HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE AR, FSHR, ESRRB MAPT 1833/4885KDM4E 1961/4885ATM 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.